Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Maxrel is a fixed-dose combination analgesic and anti-inflammatory medication marketed by Dey's Medical Stores. It contains diclofenac, a non-steroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen), an analgesic and antipyretic. Diclofenac works by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins that mediate pain and inflammation. Paracetamol acts primarily in the central nervous system to block pain impulses and reduce fever. Maxrel is indicated for the short-term management of acute pain and inflammation associated with musculoskeletal disorders, such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, muscle spasms, dental pain, and post-operative pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + paracetamol (Dey's Medical Stores).